Session » Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2794

A New Scoring System for Ultrasonographic Evaluation of Salivary Gland in Sjogren: Multireader Reliability

9:00AM-11:00AM: Abstract Number: 2785

Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 2789

Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2800

Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT

9:00AM-11:00AM: Abstract Number: 2802

Co-Occurence of Anti-Ro52/TRIM21 and Anti-TRIM38 Autoantibodies Is Associated with Higher Severity of Dry Eye in Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2788

DNA Microarray Analysis of Labial Salivary Glands in Patients with Sjögren’s Syndrome: Comparison with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 2796

Elevated Serum Immunoglobulin G Is a Prognostic Factor for Progression of Interstitial Lung Disease in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2787

Expression of Interferons Lambda in Salivary Glands of Patients with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2784

Faecal Levels of Calprotectin Are Increased in Patients with Primary Sjögren’s Syndrome and Correlates with Disease Activity

9:00AM-11:00AM: Abstract Number: 2795

Fatigue in Primary Sjögren’s Syndrome: Clinical, Laboratory, Psychometric and Biological Associations

9:00AM-11:00AM: Abstract Number: 2797

Identification of Serum Biomarker for the Glandular Dysfunction of Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2793

IL35 Serum Level Is Decreased in Patients with Primary Sjogren Syndrome, Essentially in Patients with the More Active Disease Data from the French Prospective Assess Cohort

9:00AM-11:00AM: Abstract Number: 2798

Increased Frequency of the PTPN22W* Variant in Primary Sjögren’s Syndrome-Association with Low Type I IFN Scores in Peripheral Blood

9:00AM-11:00AM: Abstract Number: 2790

Leflunomide/Hydroxychoroquine Combination Treatment Additively Inhibits T Cell Receptor/Toll-like Receptor 9-Triggered Th1 and Th17 Cytokine Secretion

9:00AM-11:00AM: Abstract Number: 2786

miR200b-5p: A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?

9:00AM-11:00AM: Abstract Number: 2792

Not Only Sjögren’s Syndrome. EBV Infection Reactivation As a Risk Factor of the Dryness Symptome Development

9:00AM-11:00AM: Abstract Number: 2803

Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting

9:00AM-11:00AM: Abstract Number: 2801

Tofacitinib Suppresses Lymphocytic Infiltration in the Salivary Gland of Non-Obese Diabetic Mice; The Animal Model of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2791

TREX-1 Variants in Sjögren’s Syndrome Related Lymphomagenesis

9:00AM-11:00AM: Abstract Number: 2799

Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].